Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD, PrecisionCHD and the HeartRisk population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
The announcement comes as cardiovascular disease remains the leading cause of death in the United States and a significant burden on employer-sponsored health plans. According to the American Heart Association, heart disease and stroke cost the U.S. health system approximately $216 billion per year in direct medical costs and lost productivity. By leveraging artificial intelligence and genetic-epigenetic data, Cardio Diagnostics aims to shift the focus from reactive treatment to early detection and prevention.
The company's flagship products use a proprietary AI-driven Integrated Genetic-Epigenetic Engine to assess an individual's risk for coronary heart disease. Epi+Gen CHD is a blood-based test that combines genetic and epigenetic markers to provide a personalized risk score. PrecisionCHD offers a more comprehensive analysis for patients with ambiguous symptoms, while the HeartRisk platform aggregates population-level data to help employers and plan administrators identify high-risk groups and tailor interventions.
The benefits conferences will provide a venue for Cardio Diagnostics to demonstrate how these tools can integrate into existing wellness programs and health plan designs. For employers, the potential impact is substantial: early identification of at-risk employees could lead to lower medical claims, reduced absenteeism, and improved employee health outcomes. Brokers and plan administrators may use the data to design more cost-effective benefit packages that prioritize preventive care.
Cardio Diagnostics' participation in these events underscores a growing trend in the healthcare industry toward precision medicine and value-based care. As employers seek to control rising healthcare costs, technologies that offer actionable insights from genomic data are gaining traction. The company's ability to provide population-level analytics through the HeartRisk platform could help benefits decision-makers move beyond traditional risk factors like age, cholesterol, and blood pressure.
For more information about Cardio Diagnostics and its product offerings, visit the company's newsroom at https://ibn.fm/CDIO. The full press release is available at https://ibn.fm/qFRHu.
Forward-looking statements in this article are subject to risks and uncertainties, as detailed in the company's filings with the SEC. Cardio Diagnostics undertakes no duty to update this information unless required by law.
